BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28347920)

  • 1. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
    Hess AK; Müer A; Mairinger FD; Weichert W; Stenzinger A; Hummel M; Budach V; Tinhofer I
    Eur J Cancer; 2017 May; 77():3-12. PubMed ID: 28347920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.
    Hess AK; Jöhrens K; Zakarneh A; Balermpas P; Von Der Grün J; Rödel C; Weichert W; Hummel M; Keilholz U; Budach V; Tinhofer I
    Oncoimmunology; 2019; 8(8):1614858. PubMed ID: 31413922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
    Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers.
    Hudcova K; Raudenska M; Gumulec J; Binkova H; Horakova Z; Kostrica R; Babula P; Adam V; Masarik M
    Tumour Biol; 2016 Sep; 37(9):12627-12633. PubMed ID: 27440205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration.
    Lerner C; Wemmert S; Bochen F; Kulas P; Linxweiler M; Hasenfus A; Heinzelmann J; Leidinger P; Backes C; Meese E; Urbschat S; Schick B
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):757-66. PubMed ID: 26621153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients.
    Summerer I; Niyazi M; Unger K; Pitea A; Zangen V; Hess J; Atkinson MJ; Belka C; Moertl S; Zitzelsberger H
    Radiat Oncol; 2013 Dec; 8():296. PubMed ID: 24373621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.
    Summerer I; Unger K; Braselmann H; Schuettrumpf L; Maihoefer C; Baumeister P; Kirchner T; Niyazi M; Sage E; Specht HM; Multhoff G; Moertl S; Belka C; Zitzelsberger H
    Br J Cancer; 2015 Jun; 113(1):76-82. PubMed ID: 26057452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of stem cell-regulating miRNAs in oral cavity and oropharynx squamous cell carcinoma.
    Brito BL; Lourenço SV; Damascena AS; Kowalski LP; Soares FA; Coutinho-Camillo CM
    J Oral Pathol Med; 2016 Oct; 45(9):647-654. PubMed ID: 26841253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3-miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post-operative radiotherapy.
    Xu X; Lu Z; Gross N; Li G; Zhang F; Lei D; Pan X
    J Cell Mol Med; 2019 Dec; 23(12):8280-8291. PubMed ID: 31578816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
    Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
    Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma.
    Li G; Ren S; Su Z; Liu C; Deng T; Huang D; Tian Y; Qiu Y; Liu Y
    Tumour Biol; 2015 May; 36(5):3949-56. PubMed ID: 25578493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
    Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
    Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.
    D'Angelo E; Fassan M; Maretto I; Pucciarelli S; Zanon C; Digito M; Rugge M; Nitti D; Agostini M
    Oncotarget; 2016 May; 7(19):28647-57. PubMed ID: 27081702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
    Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
    Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas.
    Wong N; Khwaja SS; Baker CM; Gay HA; Thorstad WL; Daly MD; Lewis JS; Wang X
    Cancer Med; 2016 Jul; 5(7):1619-28. PubMed ID: 27109697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulation of Selected MicroRNAs in Sinonasal Squamous Cell Carcinoma: Searching for Potential Prognostic Biomarkers.
    Kovaříková J; Baranová I; Laco J; Rozkošová K; Vošmíková H; Vošmík M; Dundr P; Němejcová K; Michálek J; Palička V; Chmelařová M
    Folia Biol (Praha); 2019; 65(3):142-151. PubMed ID: 31638561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary MicroRNAs for Early Detection of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in the High Altitude Mestizo Ecuadorian Population.
    Salazar-Ruales C; Arguello JV; López-Cortés A; Cabrera-Andrade A; García-Cárdenas JM; Guevara-Ramírez P; Peralta P; Leone PE; Paz-Y-Miño C
    Biomed Res Int; 2018; 2018():9792730. PubMed ID: 30584540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.